Thursday, April 07, 2011
"...In the UK, bowel cancer is the one of the top three most common cancers diagnosed in both men and women, yet nearly three quarters of the women included in the survey did not recognize the disease as being one of the three most prevalent cancers in women."
"Menopausal status has a striking effect on the dose-response for the association," said Cramer. "Premenopausal women with frequent use may have more than a threefold increase in their risk for invasive serous cancer of the ovary. Repeating these analyses in existing data sets may help clarify the association between talc and ovarian cancer."
"....Despite the costs and resources involved, leading oncology organizations
plan conferences every year. Pre- and postconference events,
including conference-revisited events, are regular rituals after large
specialty conferences. But is the physical attendance of delegates at
conferences still required? Will the oncology community rise up and
stop this perennial waste of time, effort, and money and instead use
this money for a more scientific or nobler cause?5 One suggestion
would be to create a single global research fund to which all oncology
bodies and governments contribute and to which all nations,
both developed and developing, can apply for funding of their
trials. This would greatly improve the standards of global research
and enhance scientific pursuits."
"........But no matter how much time remains, and whether the goal of care is cure, control, or comfort, we can tell our patients with absolute certainty that we will not abandon them to the unknown."
Note: online version
Highlights of April 2011
Don’s Notes 1
Managing Your Fears and Anxieties 2
May Ovarian Cancer Survivor Course 3
Improving Care through Clinical trials 4
Suggestion/request from reader 4
Survivor Anniversaries for April 5
Upcoming Event 6
Tips for Traveling by Automobile 7
Resource: CarePages.com 7
Name change: From GCF to FWC 8
National Race to End Women’s Cancer 8
Survivor Course Schedule 8
June Ovarian Cancer Survivor Course 9
Grand Finale 10
PURPOSE: Patients with Lynch syndrome are much more likely to have generally rare upper urinary tract urothelial carcinoma but not bladder urothelial carcinoma. While the risk has been quantified, to our knowledge there is no description of how this population of patients with Lynch syndrome and upper urinary tract cancer differs from the general population with upper urinary tract cancer.
MATERIALS AND METHODS: We obtained retrospective data on a cohort of patients with Lynch syndrome from the Hereditary Cancer Center in Omaha, Nebraska and compared the data to those on a control general population from western Sweden. These data were supplemented by a new survey about exposure to known risk factors.
RESULTS: Of the patients with Lynch syndrome 91% had mutations in MSH2 rather than in MSH1 and 79% showed upper tract urothelial carcinoma a mean of 15.85 years after prior Lynch syndrome-type cancer. Median age at diagnosis was 62 years vs 70 in the general population (p <0.0001). Only half of our patients had a significant smoking history and the male-to-female ratio was 0.95. Of patients with Lynch syndrome 51% had urothelial carcinoma in the ureter while it occurred in the renal pelvis in 65% of the general population (p = 0.0013). Similar numbers of high grade tumors were found in the Lynch syndrome and general populations (88% and 74%, respectively, p = 0.1108).
CONCLUSIONS: Upper urinary tract tumors develop at a younger age and are more likely to be in the ureter with an almost equal gender ratio in patients with Lynch syndrome.
It has high grade potential similar to that in the general population.
"However, Huang and colleagues found no studies in the medical literature documenting the frequency and nature of menopausal symptoms in gynecologic cancer survivors."
"Note that the percentage of gynecologic cancer survivors who reported menopausal symptoms was extremely high regardless of whether they received hormonal therapy."